| Literature DB >> 29434168 |
Naomi Mizuta1,2, Tsutomu Nakagawa1,2, Kazuhiro Yamamoto2, Tatsuya Nishioka2, Manabu Kume2, Hiroo Makimoto2, Ikuko Yano1,2, Hironobu Minami3, Midori Hirai1,2.
Abstract
Albumin-bound paclitaxel (Abraxane®, nab-paclitaxel) is not recommended to be administered concurrently or sequentially with other drugs due to concern for instability. The need to administer drugs separately increases infusion time. We evaluated the compatibility and stability of solutions containing nab-paclitaxel and other drugs, including gemcitabine hydrochloride, carboplatin, dexamethasone sodium phosphate, granisetron hydrochloride, and palonosetron hydrochloride. We visually examined changes in appearance, pH, and concentration of the mixed solutions of nab-paclitaxel and other drugs for up to 24 h. Concentration was measured using high-performance liquid chromatography (HPLC). The appearance and pH of the mixed solutions did not change for up to 24 h. The change in concentration up to 24 h was within 2%. The chromatogram did not change until 8 h. The results showed that the physical compatibility and chemical stability of nab-paclitaxel were not influenced when it was combined with other drugs until 8 h. This study suggests that nab-paclitaxel could be administered in a mixture or sequentially with other drugs to reduce administration time.Entities:
Keywords: carboplatin; compatibility ; dexamethasone sodium phosphate; gemcitabine hydrochloride; granisetron hydrochloride; nab-paclitaxel; palonosetron hydrochloride; stability
Mesh：
Substances：
Year: 2017 PMID： 29434168 PMCID： PMC5824929
Source DB: PubMed Journal: Kobe J Med Sci ISSN： 0023-2513